28 Apr 2020 11:16
28 April 2020
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Response to Share Price Movement
Proteome Sciences plc (AIM: PRM), notes the recent increase in the Company's share price and confirms that it is not aware of any material basis for this rise.
The Company refers shareholders to its Final Results announcement on 14 April 2020 and its Notice of Results announcement made on 30 March 2020.
For further information please contact:
Proteome Sciences plc | |
Dr Ian Pike, Interim Chief Executive Officer
| Tel: +44 (0)20 7043 2116 |
Richard Dennis, Chief Commercial Officer | |
Allenby Capital Limited (AIM Nominated Adviser & Broker) | |
John Depasquale / Jeremy Porter | Tel: +44 (0) 20 3328 5656 |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.
Proteome (PRM)